AlphAIAlphAI — Financial news for AI agents
investing.com$LFCR

Lifecore Biomedical earnings missed by $0.82, revenue fell short of estimates

Lifecore Biomedical (LFCR) reported Q2 EPS of -$1.08, missing estimates by $0.82, with revenue at $25.32M, below the $27.37M consensus. The stock is up 28.14% over 3 months but down 5.02% year-over-year. InvestingPro rates its financial health as 'good performance'.

Original reporting
investing.com
Published Nov 4, 2026, 4:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 4:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$LFCR
Bearish
high confidence
Mentioned
$LFCR
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$LFCRBearishMed
01

Why it matters

The earnings miss may prompt short‑term downside but longer‑term catalysts could emerge from product trials.

02

Market read

The report provides fresh financial data for a small‑cap biotech, offering traders a basis for short‑term positioning.

03

What to watch

Potential pipeline developments or upcoming regulatory approvals not mentioned in the brief could offset the earnings disappointment.

Relevance 6/10Novelty 8/10Timing: after market close

Background

Lifecore Biomedical is a micro‑cap biotech firm focused on regenerative medicine and wound care.

Company-level read

Ticker impact

$LFCRBearishHigh confidence
Context

Q2 EPS of -$1.08 missed the consensus estimate of -$0.27 by $0.82 and revenue of $25.32M fell short of the $27.37M forecast.

Expected impact

downward pressure as investors price in the earnings shortfall

Evidence & confidence

The company reported a larger-than-expected loss and lower revenue, which typically leads to a decline in share price.

Market effects

Sector

Biotech and medical device sector may see modest pullback as earnings miss highlights demand challenges.

Regional

Limited to U.S. small‑cap investors; no broader regional effect.

Global

Minimal global impact given the company's micro‑cap size.

Counterpoint

What could challenge this read

If the miss is viewed as a temporary setback, the stock could be a buying opportunity at lower levels.

Key entities

  • company
    Lifecore Biomedical

    Issuer of the earnings report.

Read at source← All news

Related articles

$LFCRHigh

Lifecore Biomedical, Inc. entered into an Agreement and Plan of Merger with Lifecore Inc. and Hazel Merger Sub, Inc. providing for the merger of Merger Sub…

LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on September 27, 2026, Lifecore Biomedical, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Lifecore Inc. (“Parent”) and Hazel Merger Sub, Inc. (“Merger Sub”) providing for the merger

SEC EDGAR 8-K
$LFCRMed

Lifecore Biomedical Reports Financial Results for the Third Quarter Ended September 30, 2026, and Provides Corporate Update

LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lifecore Biomedical Reports Financial Results for the Third Quarter Ended September 30, 2026 , and Provides Corporate Update -- Multiple New Business Wins Continue to Strengthen Growing Pipeline -- CHASKA, Minn., November 4, 2026 -- Lifecore Biomedical, Inc. (NASDAQ:

SEC EDGAR 8-K
$LFCRMed

Lifecore Biomedical, Inc. entered into an Agreement and Plan of Merger with Lifecore Inc. and Hazel Merger Sub, Inc. On October 16, 2026, the Board of…

LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on September 27, 2026, Lifecore Biomedical, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Lifecore Inc. and Hazel Merger Sub, Inc. On October 16, 2026, the Board of Directors (the “

SEC EDGAR 8-K
$HRLMedAI 8/10

Deal Dispatch: Hormel Acquires Brakebush, Onsemi buys Synaptics for $5.7 Billion, Leslie’s Pools Bankrupt

Hormel (HRL) acquires Brakebush for $1.06B; Onsemi (ON) to buy Synaptics for $5.7B; Leslie's files for bankruptcy. Valley National (VLY) to acquire Bluevine for $340M. Yext (YEXT) to acquire Flamel.ai. Lifecore (LFCR) to be acquired by Webster Equity for up to $663.7M. SoftBank completes DigitalBridge acquisition. GBTG acquired by Long Lake for $6.3B.

benzinga.com